Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF
Open Access
- 23 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 32 (9), 1121-1134
- https://doi.org/10.1038/onc.2012.136
Abstract
Lung cancer is the leading cause of cancer death worldwide. Recent data suggest that cyclic nucleotide phosphodiesterases (PDEs) are relevant in various cancer pathologies. Pathophysiological role of phosphodiesterase 4 (PDE4) with possible therapeutic prospects in lung cancer was investigated. We exposed 10 different lung cancer cell lines (adenocarcinoma, squamous and large cell carcinoma) to hypoxia and assessed expression and activity of PDE4 by real-time PCR, immunocytochemistry, western blotting and PDE activity assays. Expression and activity of distinct PDE4 isoforms (PDE4A and PDE4D) increased in response to hypoxia in eight of the studied cell lines. Furthermore, we analyzed various in silico predicted hypoxia-responsive elements (p-HREs) found in in PDE4A and PDE4D genes. Performing mutation analysis of the p-HRE in luciferase reporter constructs, we identified four functional HRE sites in the PDE4A gene and two functional HRE sites in the PDE4D gene that mediated hypoxic induction of the reporter. Silencing of hypoxia-inducible factor subunits (HIF1α and HIF2α) by small interfering RNA reduced hypoxic induction of PDE4A and PDE4D. Vice versa, using a PDE4 inhibitor (PDE4i) as a cyclic adenosine monophosphate (cAMP) -elevating agent, cAMP analogs or protein kinase A (PKA)-modulating drugs and an exchange protein directly activated by cAMP (EPAC) activator, we demonstrated that PDE4-cAMP-PKA/EPAC axis enhanced HIF signaling as measured by HRE reporter gene assay, HIF and HIF target genes expression ((lactate dehydrogenase A), LDHA, (pyruvate dehydrogenase kinase 1) PDK1 and (vascular endothelial growth factor A) VEGFA). Notably, inhibition of PDE4 by PDE4i or silencing of PDE4A and PDE4D reduced human lung tumor cell proliferation and colony formation. On the other hand, overexpression of PDE4A or PDE4D increased human lung cancer proliferation. Moreover, PDE4i treatment reduced hypoxia-induced VEGF secretion in human cells. In vivo, PDE4i inhibited tumor xenograft growth in nude mice by attenuating proliferation and angiogenesis. Our findings suggest that PDE4 is expressed in lung cancer, crosstalks with HIF signaling and promotes lung cancer progression. Thus, PDE4 may represent a therapeutic target for lung cancer therapy.This publication has 30 references indexed in Scilit:
- HIF-1α signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cellsFree Radical Biology & Medicine, 2010
- Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4Molecular Biology of the Cell, 2009
- Targeted therapies in the treatment of advanced/metastatic NSCLCEuropean Journal of Cancer, 2009
- Functional Characterization of Phosphodiesterases 4 in the Rat Carotid Body: Effect of Oxygen ConcentrationsAdvances in Experimental Medicine and Biology, 2009
- Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2008
- Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor RegressionClinical Cancer Research, 2008
- Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide SignalingAnnual Review of Biochemistry, 2007
- Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4–Regulated Compartment via Effects on Phosphoinositide 3-KinaseCancer Research, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Cyclic 3‘,5‘-Nucleotide Phosphodiesterases: Potential Targets for Anticancer TherapyChemical Research in Toxicology, 2000